EndoFectin™ HepG2 Transfection Reagent

EndoFectin™ HepG2 is a new and potent reagent optimized for transfection of the difficult-to-transfect hepatocellular carcinoma cell line HepG2.  EndoFectin™ HepG2 provides superior transfection efficiency of HepG2 cells compared with Lipofectamine® 3000 (Figure 1) and Lipofectamine® 2000 (Figure 2).

Advantages

Experiment 1: Comparison of EndoFectin™ HepG2 and Lipofectamine® 3000

Figure 1. Transfection of HepG2 cells using either EndoFectin™ Max, Lipofectamine® 2000 (LP2000) or Lipofectamine® 3000 (LP3000). Cells were transfected with a firefly luciferase-expressing plasmid. Transfection efficiencies were assessed by luciferase activity (RLU). Note: 0.15 uL/well of Lipofectamine® 3000 was used rather than 0.2 uL/well. Lipofectamine® is a trademark of Invitrogen.

Experiment 2: Comparison of EndoFectin™ HepG2 and Lipofectamine® 2000

Experiment 3: Comparison of EndoFectin™ HepG2 and electroporation

EndoFectin™ HepG2 can also provide nearly as high transfection efficiency as electroporation, meaning that you can achieve ultra-high levels of transfection with much more convenience (Figure 3).

Figure 3. Comparison of transfection efficiencies of HepG2 cells between EndoFectin™ HepG2 and electroporation. HepG2 cells were electroporated with a plasmid expressing GFP, and visualized using either visible light or fluorescence.

Note: Lipofectamine® is a registered trademark of Invitrogen

EndoFectin™ Expi293 Transfection Reagent

EndoFectin™ Expi293 is a powerful transfection reagent ideally suited for transfection of the suspension cell line Expi293F. Expi293F is the most commonly used suspension HEK293 cell line for transient expression to achieve high cell density. EndoFectin™ Expi293 provides greater transfection efficiency of Expi293 cells than Expifectamine 293 over a range of cell densities. The EndoFectin™ Expi293 kits are designed for high level of secreted (EF017 and EF018) and intracelluar (EF019 and EF020) protein expression and isolation from Expi293F cells. The kits include EndoFectin™ Expi293 transfection reagent, as well as proprietary solutions engineered to enhance protein production.

Advantages

Experiment 1: Comparison of EndoFectin™ Expi293 and Expifectamine™ 293 in plasmid transfection

A
B
Figure 1. Comparison of transfection efficiencies of the suspension cell line Expi293F between EndoFectin™ Expi293 and Expifectamine 293. Expi293F cells were cultured in 125 ml flasks and transfected with a GFP-expressing plasmid. Transfection efficiencies were quantitated as relative fluorescence units (RFU, A) and compared visually using a fluorescence microscope (B).

Experiment 2: Comparison of EndoFectin™ Expi293 and Expifectamine™ 293 in protein expression

A
B
Figure 2. Comparisons of secreted (A) and intracellular (B) protein expression in suspension cell line Expi293F between the EndoFectin™ Expi293 kit (GeneCopoeia) and the Expifectamine 293 kit (Thermo Fisher). A. Expi293F cells were transfected with a Gaussia luciferase-expressing plasmid. GeneCopoeia transfection solutions or ThermoFisher enhancers were added 16-18 hours after transfection. Gaussia luciferase expression was measured in a luminometer. B. Expi293F cells were transfected with a Firefly luciferase-expressing plasmid. GeneCopoeia transfection solution 3 or Thermo Fisher enhancers were added 16-18 hours after transfection. Firefly luciferase levels were measured in a lluminometer 48 hours after transfection.

Related Products >>

CRISPR-Fectin™ Transfection Reagent

Advantages

• High transfection efficiency for Cas9 nuclease and synthetic sgRNA
• Low toxicity to cells
• Cost effective with as low as $0.059 per transfection reaction

GeneHero™ Cas9 Nuclease genome modification in HEK293 cell line. Cas9 nuclease was co-transfected with synthetic sgRNA into the HEK293 cells using CRISPR-Fectin™ transfection reagent. Three different sgRNA targeting the HUWE gene were designed and transfected with Cas9 protein respectively. The HUWE fragments were amplified from genomic DNA and subjected to the T7 endonuclease I assay. Cleaved DNA bands are indicated by red arrows.

Related Products >>

Comparison of EndoFectin™ RNAi and Lipofectamine® 2000 in the siRNA transfection efficiency

Figure 1. EndoFectin™ RNAi and Lipofectamine®2000 transfection reagent were used to transfect 5 pmol and 10 pmol FAM-labeled β-actin-siRNA into HEK293T (A), Hela (B), and A549 (C). After 6 hours, the FAM green fluorescence intensity was observed through a fluorescence microscope.

Comparison of EndoFectin™ RNAi and Lipofectamine®3000 on eGFP gene in the knockdown effects

Figure 2. Use 1 μL EndoFectin™ RNAi and Lipofectamine®3000 transfection reagent respectively to transfect 5 pmol eGFP-siRNA into the Hela-eGFP stable cell line (cat#. SL040) in a 24-well plate. After 48 hours, changes in eGFP fluorescence intensity were observed through a fluorescence microscope.

Comparison of EndoFectin™ RNAi and Lipofectamine® RNAiMAX on eGFP gene in the knockdown effects

Figure 3. Use 1 μL EndoFectin™ RNAi and Lipofectamine® RNAiMAX transfection reagent respectively to transfect 5 pmol eGFP-siRNA into the HEK293T-eGFP stable cell line (cat#. SL039) in a 24-well plate. After 72 hours, changes in eGFP fluorescence intensity were observed through a fluorescence microscope.